A Registry on comparing the older and and newer treatment methods for Hypoparathyroidism in Greece

Prospective registry of patients affected by hypoparathyroidism of any etiology, followed at the Endocrinology, Diabetes and Metabolism clinics of the Hellenic Endocrine Network. In this study the data recorded will consist of clinical information regarding patients' gender, age at diagnosis of hypoparathyroidism, the disease cause, severity, treatments used in the past, the complications observed along with the recentmost treatments and their outcomes. These data will consist of all available information from the date off diagnosis of hypoparathyroidism to the date of study enrollment, with a minimum period of 18 months required for study participation. Additionally, prospective data on disease related complications, quality of life, treatment success or failure and care gaps will be collected over 5 years, including use of usual or newer agents. The main outcomes are the maintenance of eucalcemia (normal serum calcium corrected to albumin: 8.5-10.0mg/dl), the maintenance of normal urine calcium as measured by 24 hours urine collection (<300mg/dl/24hrs), the incidence of nephrolithiasis, nephrocalcinosis, ectopic calcifications, chronic kidney disease (eGFR<60ml/min/1.73m2), need for renal replacement therapy, cardiovascular disease events (myocardial infarctions, cerebrovascular events, peripheral arterial disesase events, significant vascular stenoses, need for percutaneous vascular interventions), arrhythmias (atrial fibrillation, other), congestive heart failure, osteoporosis, osteoporotic and non-osteoporotic fractures, patients' quality of life. The treatment that the patients involved in the Registry receive, will not be affected by their participation in the Registry, since this is not an interventional study. Each participating center will decide on the treatment strategy to follow in each case, based on clinical information and current national and international clinical practice guidelines.